Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 8-K (Current Report)
Report Date: August 11, 2026
Reporting Period: Financial results for the three and six months ended June 30, 2026.
Status: Emerging Growth Company listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The provided Form 8-K text serves as a notification of the release of financial results and incorporates the press release by reference. It does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached Exhibit 99.1 (Press Release) or the corresponding Form 10-Q for these figures.
Material Changes
The filing does not detail specific material changes in financial condition or operations within the text provided. It references the release of results for the period ended June 30, 2026, but does not quantify variances from prior periods.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a cautionary statement that comments contain forward-looking statements based on management's expectations. Actual results may differ materially due to various risks.
- Risk Factors: Risks are referenced as described in the Company's Annual Report on Form 10-K (filed March 27, 2026) and Quarterly Reports on Form 10-Q (filed May 7, 2026, and August 11, 2026).
- Guidance: No specific financial guidance or outlook numbers are provided in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the three and six months ended June 30, 2026.
- Examine the Form 10-Q filed on August 11, 2026, for detailed financial statements and management discussion.
- Verify the company's cash runway and burn rate, as these are critical for an emerging growth biotechnology firm not reporting revenue in this summary.
- Check the "Risk Factors" section of the most recent 10-K and 10-Q for updates on clinical trial progress or regulatory hurdles.